Jeff Brooks
About Jeff Brooks
Jeff Brooks is the Sr. Immuno-Oncology Business Manager-Melanoma/Lung Specialty at Bristol Myers Squibb, with a background in diabetes specialty account management and sales training.
Company
Jeff Brooks is currently working at Bristol Myers Squibb as the Sr. Immuno-Oncology Business Manager-Melanoma/Lung Specialty in Richmond, Virginia Area. His role involves overseeing the business aspects of melanoma and lung cancer treatments, specifically those related to immuno-oncology. Prior to his current role, he held various positions at Eli Lilly and Company and has extensive experience in the pharmaceutical and biotechnology industries.
Title
Jeff Brooks holds the title of Sr. Immuno-Oncology Business Manager-Melanoma/Lung Specialty. In this capacity, he specializes in managing business operations for treatments concerning melanoma and lung cancer. His role involves strategizing and implementing business plans to support the company's immuno-oncology product portfolio.
Education and Expertise
Jeff Brooks studied at the University of Tennessee-Knoxville, where he earned a Bachelor of Arts (B.A.) in Political Science and Government. He is certified in CMR (Certified Medical Representative) and holds a Six Sigma Greenbelt certification. His educational background and certifications complement his extensive experience in sales and account management in the pharmaceutical industry, particularly in oncology and diabetes care.
Professional Background
Jeff Brooks has a diverse professional background primarily in the pharmaceutical industry. He worked at Eli Lilly and Company for several years, holding positions such as Executive Diabetes Specialty-Account Management, Executive Diabetes Representative-Account Management, Associate Consultant-Diabetes National Sales Trainer, and Sr. Diabetes Sales Rep. He also worked as a Sr. Technical Recruiter at Apex Systems and as Branch Corporate Accounts Manager/Assistant Manager at Enterprise Rent-A-Car.
Achievements in Immuno-Oncology
Jeff Brooks has achieved significant milestones in his career, especially in the field of immuno-oncology. He launched multiple indications for drugs such as Opdivo and Yervoy, including treatments for Metastatic and Adjuvant Melanoma, Metastatic Non-Small Cell/Small Cell Lung Cancer, and Malignant Pleural Mesothelioma. His expertise in these areas has contributed to his recognition, such as receiving the 2018 Winner’s Circle Award & Trip to Kauai, Hawaii based on portfolio sales results.